Schorno Dean L 4

What Happened
Dean L. Schorno, Chief Financial Officer of Rigel Pharmaceuticals (RIGL), disposed of 5,488 shares on February 2, 2026 at $36.01 per share, a total value of approximately $197,623. The Form 4 reports the transaction type as "F" — payment of exercise price or tax liability — indicating shares were used to cover tax/option-related obligations rather than a standard open-market sale. The filing (Feb 4, 2026) notes 500 of the shares included were acquired under the issuer's stock purchase plan.

Key Details

• Transaction date: 2026-02-02; price: $36.01 per share; total value ≈ $197,623
• Shares disposed: 5,488 (reported as "Disposed" under code F)
• Footnote: F1 — includes 500 shares acquired under the issuer's stock purchase plan
• Filing date: 2026-02-04 (filed two days after the transaction; appears within the typical Form 4 reporting window)
• Shares owned after the transaction: not specified in the provided excerpt

Context
Code F transactions generally reflect withholding of shares to satisfy tax liabilities or exercise-price obligations (a common part of option exercises or share settlements). Such withholdings are routine administrative actions and do not necessarily indicate a change in the insider's view of the company.